Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 2/20 | 0.40 |
| ▸ | NPY4R | P50391 | 6/20 | 0.40 |
| ▸ | NPY1R | P25929 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 3/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13607813 | 0.90 | TAS1R3 (0.42) | TAS1R3TAS1R1ERAP2OPRK1GHSR | |
| SCHEMBL13342817 | 0.85 | TAS1R3 (0.43) | TAS1R3TAS1R1 | |
| SCHEMBL13342807 | 0.84 | MEN1 (0.45) | ALDH1A1GAA | |
| SCHEMBL13342811 | 0.82 | SCN4A (0.47) | OPRK1MME | |
| SCHEMBL16153110 | 0.82 | TAS1R3 (0.47) | TAS1R3TAS1R1ALDH1A1GAA | |
| SCHEMBL13342824 | 0.78 | PSMB5 (0.48) | ERAP2OPRK1ALDH1A1ERAP1 | |
| SCHEMBL13342793 | 0.77 | TSHR (0.50) | ALDH1A1GAA | |
| SCHEMBL13342790 | 0.75 | AAK1 (0.50) | TAS1R3TAS1R1ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL15512388 | 0.75 | DPP8 (0.47) | ERAP2NPY4RNPY1RLNPEPERAP1 | |
| SCHEMBL13342821 | 0.75 | NPSR1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7626042-B2 | O-substituted hydroxyaryl derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | TAS1R3 4794/4885TAS1R1 4668/4885ERAP2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.